SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 219.55

Change

-4.20 (-1.88)%

Market Cap

USD 0.66B

Volume

600.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.34 (+0.68%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.11 (+0.69%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.18 (+0.69%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.17 (+0.60%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.30 (+1.23%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.13 (+0.28%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+1.44 (+1.02%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.31 (+0.61%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.48 (+0.49%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.02 (+0.54%)

USD 80.38B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.12% 55% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.12% 56% F 59% D-
Trailing 12 Months  
Capital Gain 13.00% 45% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.00% 46% F 50% F
Trailing 5 Years  
Capital Gain 46.11% 71% C- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.11% 71% C- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 8.78% 65% D 63% D
Dividend Return 8.78% 63% D 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.38% 67% D+ 74% C
Risk Adjusted Return 104.75% 96% N/A 96% N/A
Market Capitalization 0.66B 70% C- 62% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike